Lundbeck
Lundbeck, officially known as H. Lundbeck A/S, is a global pharmaceutical company headquartered in Denmark (DK). Founded in 1915, Lundbeck has established itself as a leader in the neuroscience sector, focusing on the treatment of brain disorders such as depression, schizophrenia, and Alzheimer's disease. With a strong presence in Europe, North America, and Asia, the company is dedicated to improving the lives of patients through innovative therapies. Lundbeck's core products include a range of unique medications that address complex neurological conditions, setting them apart in a competitive market. The company has achieved notable milestones, including the development of several breakthrough treatments that have significantly impacted patient care. Renowned for its commitment to research and development, Lundbeck continues to strengthen its position as a key player in the global pharmaceutical industry.
DitchCarbon Score
How does Lundbeck's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Lundbeck's score of 80 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Lundbeck's reported carbon emissions
In 2024, Lundbeck reported total carbon emissions of approximately 20409000 kg CO2e for Scope 1 and 7088000 kg CO2e for Scope 2 on a market-based approach, with a total of about 134154000 kg CO2e for Scope 3 emissions. The breakdown of Scope 3 emissions includes approximately 14560000 kg CO2e from business travel and about 112491000 kg CO2e from purchased goods and services. Lundbeck has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its value chain by 2050. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 42% by 2029 from a 2019 baseline. Additionally, it aims to cut Scope 3 emissions from purchased goods and services, upstream transportation, and business travel by 25% within the same timeframe. For long-term goals, Lundbeck targets a 90% reduction in absolute emissions across all scopes (1, 2, and 3) by 2050, also based on 2019 levels. Notably, the company plans to exclusively use 100% renewable electricity for its EU sites by 2025, further demonstrating its commitment to sustainability. Lundbeck's emissions data and targets are sourced directly from the company, with no cascaded data from parent organizations. The company is actively working towards its sustainability goals within the pharmaceutical sector, aligning with industry standards for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 6,626,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 13,317,000 | - | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Lundbeck is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
